DiaSorin (OTCMKTS:DSRLF) Sees Strong Trading Volume – Here’s Why

DiaSorin S.p.A. (OTCMKTS:DSRLF) shares saw strong trading volume on Tuesday . 500 shares were traded during mid-day trading, an increase of 39% from the previous session’s volume of 361 shares.The stock last traded at $80.00 and had previously closed at $81.00.

Analysts Set New Price Targets

A number of research firms have issued reports on DSRLF. Zacks Research raised DiaSorin to a “hold” rating in a research report on Tuesday, May 12th. BNP Paribas Exane downgraded DiaSorin from a “neutral” rating to an “underperform” rating in a report on Tuesday, July 7th. UBS Group lowered DiaSorin from a “buy” rating to a “neutral” rating in a research note on Thursday, April 9th. Piper Sandler started coverage on DiaSorin in a report on Thursday, June 11th. They set a “neutral” rating for the company. Finally, Deutsche Bank Aktiengesellschaft lowered shares of DiaSorin from a “hold” rating to a “sell” rating in a report on Wednesday, June 17th. Two equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold”.

DiaSorin Stock Performance

The stock has a 50-day moving average price of $75.55 and a 200-day moving average price of $76.32.

About DiaSorin

DiaSorin S.p.A. is an Italy‐based global biotechnology company specializing in the development, manufacture and marketing of in vitro diagnostic products. Headquartered in Saluggia, DiaSorin serves clinical laboratories, hospitals and physician offices with a broad portfolio of immunodiagnostic assays and molecular diagnostic tests. The company’s shares trade on the Milan Stock Exchange and are available in the United States as over‐the‐counter (OTC) securities under the symbol DSRLF.

At the core of DiaSorin’s business are immunodiagnostic systems that measure antibodies, antigens and hormones in human samples.